WallStreetZenWallStreetZen

NASDAQ: HLVX
Hillevax Inc Stock

Overview
ForecastEarningsRevenueDividendOwnership
$1.94+0.01 (+0.52%)
Updated Apr 30, 2025
HLVX Price
$1.94
Fair Value Price
$2.64
Market Cap
$97.27M
52 Week Low
$1.34
52 Week High
$16.31
P/E
-0.65x
P/B
0.63x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$147.27M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.25
Operating Cash Flow
-$109M
Beta
1.09
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

HLVX Overview

HilleVax, Inc., a clinical-stage biopharmaceutical company, develops novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. Founded as MokshaCo, Inc. in 2020, the company changed its name in 2021. HilleVax is headquartered in Boston, MA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine HLVX's potential to beat the market

DSell
  • Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

C
Value
C
Growth
C
Momentum
D
Sentiment
F
Safety
C
Financials
D
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
HLVX
Ranked#231 of 462

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Protalix Biotherapeutics (PLX)
$3.07A
Aurinia Pharmaceuticals (AUPH)
$8.24A
Catalyst Pharmaceuticals (CPRX)
$24.29A
View Top Biotech Stocks

Be the first to know about important HLVX news, forecast changes, insider trades & much more!

HLVX News

Overview

Due Diligence Score

–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HLVX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HLVX ($1.94) is undervalued by 26.62% relative to our estimate of its Fair Value price of $2.64 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
HLVX ($1.94) is significantly undervalued by 26.62% relative to our estimate of its Fair Value price of $2.64 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
HLVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HLVX due diligence checks available for Premium users.

Valuation

HLVX fair value

Fair Value of HLVX stock based on Discounted Cash Flow (DCF)

Price
$1.94
Fair Value
$2.64
Undervalued by
26.62%
HLVX ($1.94) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HLVX ($1.94) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HLVX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

HLVX price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-0.65x
Industry
-162.28x
Market
29.18x

HLVX price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
0.63x
Industry
4.45x
HLVX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

HLVX's financial health

Profit margin

Revenue
$0.0
Net Income
-$33.9M
Profit Margin
0%
HLVX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials

Assets to liabilities

Assets
$192.7M
Liabilities
$38.2M
Debt to equity
0.25
HLVX's short-term assets ($178.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HLVX's short-term assets ($178.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HLVX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$18.2M
Investing
$68.9M
Financing
$0.0
HLVX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

HLVX vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
HLVXD$97.27M+0.52%-0.65x0.63x
PLRXF$97.37M+7.43%-0.46x0.32x
VIGLF$98.01M+9.38%-1.01x1.37x
BDTXC$96.33M+6.25%-1.34x1.16x
ENTX–$98.56M-2.69%-8.68x12.20x
View Top Biotech Stocks

Hillevax Stock FAQ

What is Hillevax's quote symbol?

(NASDAQ: HLVX) Hillevax trades on the NASDAQ under the ticker symbol HLVX. Hillevax stock quotes can also be displayed as NASDAQ: HLVX.

If you're new to stock investing, here's how to buy Hillevax stock.

What is the 52 week high and low for Hillevax (NASDAQ: HLVX)?

(NASDAQ: HLVX) Hillevax's 52-week high was $16.31, and its 52-week low was $1.34. It is currently -88.1% from its 52-week high and 44.78% from its 52-week low.

How much is Hillevax stock worth today?

(NASDAQ: HLVX) Hillevax currently has 50,141,064 outstanding shares. With Hillevax stock trading at $1.94 per share, the total value of Hillevax stock (market capitalization) is $97.27M.

Hillevax stock was originally listed at a price of $19.09 in Apr 29, 2022. If you had invested in Hillevax stock at $19.09, your return over the last 3 years would have been -89.84%, for an annualized return of -53.33% (not including any dividends or dividend reinvestments).

How much is Hillevax's stock price per share?

(NASDAQ: HLVX) Hillevax stock price per share is $1.94 today (as of Apr 30, 2025).

What is Hillevax's Market Cap?

(NASDAQ: HLVX) Hillevax's market cap is $97.27M, as of May 1, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Hillevax's market cap is calculated by multiplying HLVX's current stock price of $1.94 by HLVX's total outstanding shares of 50,141,064.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.